Filtration of Glass Delamination Particles with West Pharmaceutical Vial Adapters

References

1. 1.↵
   1. Haines D.,
   2. Scheumann V.,
   3. Rothhaar U.,
   4. Problem A. I.

   Glass flakes: Pre-testing stops a big problem before it even starts. Contract Pharma 2013, June 5, 92–97.
2. 2.↵
   1. Iacocca R. G.,
   2. Toltl N.,
   3. Allgeier M.,
   4. Bustard B.,
   5. Dong X.,
   6. Foubert M.,
   7. Hofer J.,
   8. Peoples S.,
   9. Shelbourn T.

   Factors affecting the chemical durability of glass used in the pharmaceutical industry. AAPS PharmSciTech 2010, 11(3), 1340–1349.

   OpenUrlPubMed
3. 3.↵
   USP <1660> Evaluation of the Inner Surface Durability of Glass Containers. USP 37; U.S. Pharmacoepial Convention: Rockville, MD, 2014.
4. 4.↵
   1. Ratnaswamy G.,
   2. Hair A.,
   3. Li G.,
   4. Thirumangalathu R.,
   5. Nashed-Samuel Y.,
   6. Brych L.,
   7. Dharmavaram V.,
   8. Wen Z. Q.,
   9. Fujimori K.,
   10. Jing W.,
   11. Sethuraman A.,
   12. Swift R.,
   13. Ricci M. S.,
   14. Piedmonte D. M.

   A case study of nondelamination glass dissolution resulting in visible particles: implications for neutral pH formulations. J. Pharm. Sci. 2014, 103(4), 1104–1411.

   OpenUrlPubMed
5. 5.↵
   1. Guadagnino E.,
   2. Zuccato D.

   Delamination propensity of pharmaceutical glass containers by accelerated testing with different extraction media. PDA J. Pharm. Sci. Technol. 2012, 66(2), 116–125.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   U.S. Food and Drug Aministration. Strategic plan for preventing and mitigating drug shortages. U.S. Department of Health and Human Services, U.S. Food and Drug Administration: Silver Spring, MD, 2013.
7. 7.↵
   1. Diebold K. J.

   Microscopical evaluation of glass delamination in pharmaceutical vials: a look at three different vial manufacturers. Microscope-Chicago 2004, 52(1), 41–48.

   OpenUrl
8. 8.↵
   1. Bukofzer S.,
   2. Ayres J.,
   3. Chavez A.,
   4. Devera M.,
   5. Miller J.,
   6. Ross D.,
   7. Shabushnig J.,
   8. Vargo S.,
   9. Watson H.,
   10. Watson R.

   Industry perspective on the medical risk of visible particles in injectable drug products. PDA J. Pharm. Sci. Technol. 2015, 69(1), 123–139.

   OpenUrlFREE Full Text
9. 9.↵
   1. Lehr H.,
   2. Brunner J.,
   3. Rangoonwala R.,
   4. Kirkpatrick C. J.

   Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am. J. Resp. Crit. Care Med. 2002, 165(4), 514–520.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Yorioka K.,
    2. Oie S.,
    3. Oomaki M.,
    4. Imamura A.,
    5. Kamiya A.

    Particulate and microbial contamination in in-use admixed intravenous infusions. Biol. Pharm. Bull. 2006, 29, 2321–2323.

    OpenUrlPubMed
11. 11.↵
    1. Puntis J. W.,
    2. Wilkins K. M.,
    3. Ball P. A.,
    4. Rushton D. I.,
    5. Booth I. W.

    Hazards of parenteral treatment: Do particles count? Arch. Dis. Child. 1992, 67(12), 1475–1477.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Lye S. T.,
    2. Hwang N. C.

    Glass particle contamination: Is it here to stay? Anaesthesia 2003, 58(1), 93–94.

    OpenUrlPubMed
13. 13.↵
    1. Turco S. J.,
    2. Davis N. M.

    Detrimental effects of particulate matter on the pulmonary circulation. JAMA 1971, 217(1), 81–82.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Walpot H.,
    2. Frankie R. P.,
    3. Burchard W. G.,
    4. Agternkamp C.

    The filter effectiveness of common 15-micron filters (DIN 58362). II: Scanning electron microscopy and roentgen analysis. Infusionstherapie 1989, 16(3), 133–139.

    OpenUrlPubMed
15. 15.↵
    1. Schroeder H. G.,
    2. DeLuca P. P.

    Particulate matter assessment of a clinical investigation on filtration and infusion phlebitis. Am. J. Health-Syst. Pharm. 1976, 33(6), 543–546.

    OpenUrlAbstract
16. 16.↵
    1. DeLuca P. P.,
    2. Rapp R. P.,
    3. Bivins B.,
    4. McKean H.

    E; Griffen, W. O. Filtration and infusion phlebitis: a double-blind prospective clinical study. Am. J. Health-Syst. Pharm. 1975, 32(10), 1001–1007.

    OpenUrlAbstract
17. 17.↵
    1. Lehr H.,
    2. Brunner J.,
    3. Rangoonwala R,
    4. Kirkpatrick C. J.

    Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am. J. Resp. Crit. Care Med. 2002, 165 (4), 514–520.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Sabon R. L.,
    2. Cheng E. Y.,
    3. Stommel K. A.,
    4. Hennen C. R.

    Glass particle contamination: influence of aspiration methods and ampule types. Anesthesiology 1989, 70(5), 859–862.

    OpenUrlPubMed
19. 19.↵
    1. Ball P. A.

    Intravenous in-line filters: filtering the evidence. Curr. Opin. Clin. Nutr. Metab. Care 2003, 6(3), 319–325.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    This is based on internal research performed at West Pharmaceutical Services.
21. 21.↵
    1. Bethune K.,
    2. Allwood M.,
    3. Grainger C.,
    4. Wormleighton C.

    Use of filters during the preparation and administration of parenteral nutrition: position paper and guidelines prepared by a British pharmaceutical nutrition group working party. Nutrition 2001, 17(5), 403–408.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Mitzenmacher M.,
    2. Upfal E.

    Probability and Computing: Randomized Algorithms and Probabilistic Analysis; Cambridge University Press: Cambridge, U.K., 2005.
23. 23.↵
    1. Haight F. A.

    Handbook of the Poisson Distribution; John Wiley & Sons: New York, 1967.
24. 24.↵
    “Statistics: The Poisson Distribution”, Umass.edu, https://www.umass.edu/wsp/resources/poisson/, 2007.
25. 25.↵
    1. Singpurwalla D.

    A Handbook of Statistics; Bookboon, http://bookboon.com/en/a-handbook-of-statistics-ebook 2013; 65–69.